<DOC>
	<DOCNO>NCT00770315</DOCNO>
	<brief_summary>This study evaluate efficacy safety ragweed sublingual tablet ( SCH 39641/MK-3641/Amb 1-U ) compare placebo participant ragweed-induced rhinoconjunctivitis one-year period . It expect ragweed allergic participant one active arm trial decrease allergic rhinoconjunctivitis symptom require less allergy rescue medication ragweed pollen season .</brief_summary>
	<brief_title>Efficacy Long-Term Safety Ragweed ( Ambrosia Artemisiifolia ) Sublingual Tablet ( SCH 39641 ) Adults With History Ragweed-Induced Rhinoconjunctivitis With Without Asthma ( Study P05234 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<criteria>Must clinical history significant ragweedinduced allergic rhinoconjunctivitis least 2 year duration , without asthma receive treatment previous ragweed season ( RS ) . Must positive skin prick test response Ambrosia artemisiifolia Screening Visit . Must positive specific immunoglobulin E ( IgE ) Ambrosia artemisiifolia Screening Visit . Must force expiratory volume one second ( FEV1 ) least 70 % predict Screening Visit . Safety laboratory test vital sign conduct Screening Visit must within normal limit clinically acceptable investigator/sponsor . Must willing give write informed consent able adhere dose visit schedule . Female participant childbearing potential must use medically acceptable adequate form birth control . These include : hormonal contraceptive prescribe physician ( oral , hormonal vaginal ring , hormonal implant depot injectable ) ; medically prescribe intrauterine device ; medically prescribe topicallyapplied transdermal contraceptive patch ; doublebarrier method ( eg , condom combination spermicide ) . Female participant childbearing potential counseled appropriate use birth control study . Female participant currently sexually active must consent use one abovementioned method becomes sexually active study . Female participant childbearing potential must negative urine pregnancy test Screening Visit . Women surgically sterilize least 1 year postmenopausal consider childbearing potential . Clinical history symptomatic seasonal allergic rhinitis and/or asthma receive regular medication , due another potentially overlap RS . Clinical history significant symptomatic perennial allergic rhinitis and/or asthma due allergen participant regularly expose . Receipt immunosuppressive treatment within 3 month prior Screening Visit ( except steroid allergic asthma symptom ) . Clinical history severe asthma . Asthma require medium high dose inhale corticosteroid ( ICS ) . History anaphylaxis cardiorespiratory symptom . History chronic urticaria angioedema . Clinical history chronic sinusitis 2 year prior Screening Visit . Current severe atopic dermatitis . Breastfeeding , pregnancy , intend become pregnant . Had previous treatment immunotherapy ragweed allergen allergen 5 year prior Screening Visit . History allergy , hypersensitivity intolerance ingredient investigational medicinal product ( except Ambrosia artemisiifolia ) , rescue medication , selfinjectable epinephrine . Any clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study . Use investigational drug within 30 day Screening Visit . Participation clinical study . Being family member study staff . Inability meet medication washout requirement . Unlikely able complete trial , likely travel extend time RS . Clinically significant abnormal vital sign lab value . Participation study another site . Randomized study . Inability comply use selfinjectable epinephrine . Greater risk develop adverse reaction epinephrine administration . History selfinjectable epinephrine use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>